KERX Financial Facts

Total research and development: 9.59M
Total operating expenses: 29M
See Full Income Statement

Total current assets: 200.75M
Other assets, net: 307K
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 8/5/15 EPS Growth Rate -8.3%
Average EPS % Beat Rate -12.2% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +1.2% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A Details
8/8/11 Q211 -$0.05-$0.03 -$0.02$5M$5M N/A Details
5/4/15 Q115 -$0.28-$0.30 +$0.02$1.2M$2.45M N/A Details
2/27/15 Q414 -$0.44-$0.37 -$0.07$569K$1.39M N/A Details
11/6/14 Q314 -$0.38-$0.27 -$0.11$256K$150K N/A Details
5/8/12 Q112 -$0.13-$0.12 -$0.01N/AN/A N/A Details
2/29/12 Q411 -$0.12-$0.14 +$0.02N/AN/A N/A Details